Clinical observation of renal artery stenosis treated with PCSK9 inhibitor.

Fali Zhao, Qianping Gao, Bo Jiang, Han Li, Yawen Wu, Wei Yang

Abstract readObservational Study

In one paragraph

Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fali ZhaoDepartment of Cardiology, The First Affiliated Hospital of Harbin Medical University, No.23, Post Street, Nangang District, Harbin, Heilongjiang, 150001, China. zhaofali320@126.com.

Qianping GaoDepartment of Cardiology, The First Affiliated Hospital of Harbin Medical University, No.23, Post Street, Nangang District, Harbin, Heilongjiang, 150001, China.

Bo JiangDepartment of Cardiology, The First Affiliated Hospital of Harbin Medical University, No.23, Post Street, Nangang District, Harbin, Heilongjiang, 150001, China.

Han LiDepartment of Ultrasound Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China.

Yawen WuDepartment of Cardiology, The First Affiliated Hospital of Harbin Medical University, No.23, Post Street, Nangang District, Harbin, Heilongjiang, 150001, China.

Wei YangDepartment of Medical Laboratory Science, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China.

Funding

China Academy of Management Research Institute, Institute of Education Science, Key Research Project of Scientific and Educational Innovation KJCX209-2Postgraduate Innovation Research Project Fund of Harbin Medical University YJSCX2020-29HYD

6 · The paper itself

Abstract

backgroundRenal artery stenosis (RAS) is a major cause of atherosclerotic secondary hypertension, and interventional therapy carries notable risks. This study evaluated the effects of the PCSK9 inhibitor evolocumab plus statin therapy on lipid profiles, renal artery hemodynamics, and renal function in patients with coronary artery disease (CAD) and RAS.

methodsIn this single-center retrospective cohort, 57 CAD patients with RAS (July 2019-May 2025) underwent bilateral renal artery ultrasonography and ≥ 1 month follow-up. Patients received either PCSK9 inhibitor therapy (n = 25; evolocumab 140 mg biweekly + atorvastatin 20 mg/day) or standard statin therapy alone (n = 32; atorvastatin 20 mg/day as control). Changes in LDL-C, TC, TG, Lp(a), serum creatinine (Cr), and RAU_RRA/RAU_LRA were compared. Analyses included hierarchical clustering, principal component analysis (PCA), t-tests, and Spearman correlation.

resultsBetween-group comparisons after treatment showed that the combination therapy group was significantly superior to the control group in terms of lipids, creatinine, and renal artery parameters (all P < 0.05), while Lp(a) showed an increasing trend. Within-group pre-post comparisons showed improving trends in various indicators, but only some lipid parameters reached statistical significance.

conclusionIn this exploratory study, evolocumab plus statin was associated with improved lipids, renal artery hemodynamics, and potential renal benefit. Due to the small sample size, non-randomized design, and non-significant within-group creatinine change, results should be interpreted cautiously and validated in prospective studies.

Indexed as

Antibodies, Monoclonal, HumanizedAnticholesteremic AgentsAtorvastatinDyslipidemiasHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsRenal Artery ObstructionSerine Proteinase InhibitorsAgedBiomarkersDrug Therapy, CombinationFemaleHemodynamicsHumansLipidsMaleAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsAtorvastatinBiomarkersevolocumabHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Serine Proteinase InhibitorsLipidPCSK9 inhibitorRenal artery stenosisRenal function

Identifiers

PMID42393528

DOI10.1186/s12872-026-06204-x

PMCPMC13599175

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.